In this cohort of hospitalized COVID-19 patients, novel inflammatory biomarkers, including GDF-15, suPAR and PIVKA II were associated with some patient’s clinical characteristics, complications, and poor outcomes. This evidence concerns the gene GDF15 and COVID-19.